Wang J, Jiang C, Zhang K, Lan X, Chen X, Zang W, et al
Given their widespread use and overall safety profile, DPP-4 inhibitors remain a first-line or second-line treatment for many Japanese individuals with type 2 diabetes, though careful monitoring is warranted in specific high-risk populations
Side Effect Profiles And Tolerance Patterns Both medications share similar side effect categories, but intensity and timing can differ
Cell Stem Cell 17 , 585596 (2015)
Our sourcing approach emphasizes consistency, communication, and responsiveness, helping customers maintain confidence throughout the purchasing process